Literature DB >> 8636300

Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.

R A Bebb1, B D Anawalt, R B Christensen, C A Paulsen, W J Bremner, A M Matsumoto.   

Abstract

Studies using high dose testosterone (T) administration in normal men as a male contraceptive have resulted in azoospermia rates of only 50-70%. Previous studies of T and progestogen combinations have shown comparable rates of azoospermia, but have been uncontrolled or used T in doses less than that associated with maximal suppression of sperm production. We conducted a randomized, placebo-controlled, single blind trial comparing 6 months of T enanthate administration (100 mg, im, weekly) with the same dose of T enanthate in conjunction with the progestogen levonorgestrel (LNG; 500 micrograms, orally, daily) in 36 normal men, aged 20-42 yr (n = 18 in each group). The primary end points were induction of azoospermia or severe oligospermia (< 3 million sperm/mL). The combination of T plus LNG was much more effective in suppressing sperm production than T alone. Sixty-seven percent of the T plus LNG group (12 of 18) and 33% of the T alone group (6 of 18) achieved azoospermia by 6 months (P = 0.06). Severe oligospermia or azoospermia developed in 94% of the T plus LNG (17 of 18) group compared to 61% of the T alone group (11 of 18; P < 0.05). T plus LNG also suppressed sperm production more rapidly than T alone. Time to azoospermia was 9.9 +/- 1.0 vs. 15.3 +/- 1.9 weeks in the T plus LNG and T alone groups, respectively (mean +/- SEM; P < 0.05). Serum high density lipoprotein cholesterol decreased 21.7 +/- 3.6% in men given T plus LNG (P < 0.05), compared to only a 1.8 +/- 3.8% decrease in men in the T alone group. Average weight gain was 5.3 +/- 0.8 kg in the T plus LNG group and 2.3 +/- 0.9 kg in the T alone group (P < 0.05). Acne and increase in hemoglobin were similar in the two groups. We conclude that combination hormonal therapy with T plus a progestogen might offer a reversible male contraceptive approach with a more rapid onset of action and more reliable induction of both azoospermia and severe oligospermia than T alone.

Entities:  

Keywords:  Americas; Androgens; Biology; Comparative Studies; Contraception; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Male--administraction and dosage; Contraceptive Agents, Male--side effects; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents--administraction and dosage; Contraceptive Agents--side effects; Developed Countries; Endocrine System; Family Planning; Hormones; Levonorgestrel--administraction and dosage; North America; Northern America; Physiology; Research Methodology; Research Report; Spermatogenesis Blocking Agents; Studies; Testosterone--administraction and dosage; United States; Washington

Mesh:

Substances:

Year:  1996        PMID: 8636300     DOI: 10.1210/jcem.81.2.8636300

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  28 in total

1.  Characteristics associated with suppression of spermatogenesis in a male hormonal contraceptive trial using testosterone and Nestorone(®) gels.

Authors:  M Y Roth; N Ilani; C Wang; S T Page; W J Bremner; R S Swerdloff; C Dart; R Sitruk-Ware; N Kumar; D Blithe; J K Amory
Journal:  Andrology       Date:  2013-09-30       Impact factor: 3.842

Review 2.  Male hormonal contraception: potential risks and benefits.

Authors:  Niloufar Ilani; Ronald S Swerdloff; Christina Wang
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

3.  Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive.

Authors:  Prasanth Surampudi; Stephanie T Page; Ronald S Swerdloff; Jean Jacques Nya-Ngatchou; Peter Y Liu; John K Amory; Andrew Leung; Laura Hull; Diana L Blithe; Jason Woo; William J Bremner; Christina Wang
Journal:  Andrology       Date:  2014-05-02       Impact factor: 3.842

Review 4.  Diagnosis and Management of Anabolic Androgenic Steroid Use.

Authors:  Bradley D Anawalt
Journal:  J Clin Endocrinol Metab       Date:  2019-07-01       Impact factor: 5.958

5.  Complete sperm suppression in rats with dienogest plus testosterone undecanoate is facilitated through apoptosis in testicular cells.

Authors:  Rekha Meena; Man Mohan Misro; Debidas Ghosh
Journal:  Reprod Sci       Date:  2012-11-30       Impact factor: 3.060

Review 6.  Male contraception.

Authors:  John K Amory
Journal:  Fertil Steril       Date:  2016-09-24       Impact factor: 7.329

7.  Effect of sexual intercourse on the absorption of levonorgestrel after vaginal administration of 0.75 mg in Carraguard gel: a randomized, cross-over, pharmacokinetic study.

Authors:  Vivian Brache; Horacio Croxatto; Narender Kumar; Regine Sitruk-Ware; Leila Cochón; Veronica Schiappacasse; Irving Sivin; Carla Muñoz; Robin Maguire; Anibal Faundes
Journal:  Contraception       Date:  2008-11-21       Impact factor: 3.375

Review 8.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 9.  Beyond the Condom: Frontiers in Male Contraception.

Authors:  Mara Y Roth; John K Amory
Journal:  Semin Reprod Med       Date:  2016-03-04       Impact factor: 1.303

10.  Association of progesterone receptor gene polymorphism with male infertility and clinical outcome of ICSI.

Authors:  Sanjukta Sen; Abhijit Dixit; Chitra Thakur; Jyotsna Gokral; Indira Hinduja; Kusum Zaveri; Kumarasamy Thangaraj; Deepak Modi
Journal:  J Assist Reprod Genet       Date:  2013-08-11       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.